Literature DB >> 7895607

Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.

L M Shaw1, H S Bonner, D Q Brown.   

Abstract

This study investigated the metabolism of the radio- and chemoprotector compound, WR-2721 [amifostine; s-2-(3- aminopropylamino)ethylphosphorothioate], in the Balb/c mouse. The latter was selected for these studies because considerable radiation protection data have been published for this mouse strain using the WR-2721 dose, route of administration, and optimal time for protection following intraperitoneal injection used herein. It is known that protection requires conversion of the parent drug to its free thiol metabolite, WR-1065, in cultured cells. Because it is possible that metabolites of WR-1065 could be involved in protection and because thiols are metabolically very reactive molecules, we investigated the metabolism of WR-2721 using electrochemical detection-HPLC methods. The following are the major findings in this study: 1) WR-2721 drug was rapidly cleared from the bloodstream. Blood concentration of the parent drug decreased 10-fold 30 min after administration from the maximal observed value at 5 min 2) WR-1065 rapidly appeared in the perchloric acid (PCA)-soluble fraction of normal solid tissues. The highest WR-1065 concentrations in liver and kidney were 965 and 2195 mumol/kg, respectively, 10 min after parent drug administration, whereas for heart and small intestine the highest values were 739 and 410 mumol/kg at 30 min. 3) WR-1065 accumulated in the PCA-soluble fraction of two experimental tumors at a lower rate than for the other tissues.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7895607

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Amifostine induces antioxidant enzymatic activities in normal tissues and a transplantable tumor that can affect radiation response.

Authors:  David J Grdina; Jeffrey S Murley; Yasushi Kataoka; Kenneth L Baker; Rangesh Kunnavakkam; Mitchell C Coleman; Douglas R Spitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-01       Impact factor: 7.038

2.  In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.

Authors:  Zeinab Yaseen; Christian Michoudet; Gabriel Baverel; Laurence Dubourg
Journal:  Pediatr Nephrol       Date:  2008-01-18       Impact factor: 3.714

3.  The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A.

Authors:  S Dedieu; X Canron; H R Rezvani; M Bouchecareilh; F Mazurier; R Sinisi; M Zanda; M Moenner; A Bikfalvi; S North
Journal:  BMC Med       Date:  2010-03-24       Impact factor: 8.775

4.  Mammalian cell polyamine homeostasis is altered by the radioprotector WR1065.

Authors:  J L Mitchell; J Rupert; A Leyser; G G Judd
Journal:  Biochem J       Date:  1998-10-15       Impact factor: 3.857

Review 5.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

6.  Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.

Authors:  Trevor McKibbin; John C Panetta; Maryam Fouladi; Amar Gajjar; Feng Bai; M Fatih Okcu; Clinton F Stewart
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

7.  Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.

Authors:  A E Korst; E Boven; M L van der Sterre; A M Fichtinger-Schepman; W J van der Vijgh
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.